Cerenome Launches CNSide® CSF Molecular Profile Tests
Key Highlights
- ➤CNSide launches two CSF molecular profiling tests for U.S. ordering October 12, 2026
- ➤Tests analyze over 300 cancer-related genes and over 1,600 RNA transcripts
- ➤Molecular Profile expands CNSide beyond leptomeningeal metastases to broader CNS cancers
- ➤Study identified cancer-related molecular findings in 78.4% of 1,391 CSF specimens
- ➤Cerenome has performed over 11,000 CNSide tests at more than 120 U.S. cancer institutions
Expert Statements
Russell Bradley, President and General Manager of CNSide Diagnostics, LLC
“Physicians managing cancer in the CNS need more than confirmation that disease is present. They need information they can act on.”
Russell Bradley, President and General Manager of CNSide Diagnostics, LLC
“Molecular Profile adds DNA and RNA findings, including potentially actionable alterations, to the cellular information CNSide already provides, and extends CNSide beyond leptomeningeal metastases to primary CNS tumors and hematologic cancers involving the CNS.”
HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the United States beginning October 12, 2026: * CNSide(®) CSF Molecular Profile – Solid Tumor (DNA & RNA) * CNSide(®) CSF Molecular Profile – Hematologic Malignancies (DNA & RNA) CNSide CSF Molecular Profile provides comprehensive DNA and RNA profiling of CNS disease biology from cerebrospinal fluid. The tests analyze more than 300 cancer-related genes in cell-free DNA and more than 1,600 transcripts by RNA sequencing, enabling broad characterization of genomic and transcriptomic alterations, including sequence variants, copy-number alterations, and gene fusions. The Hematologic Malignancies test also supports molecular assessment of clonality.
Get started
Create a free account to read the full story.